Ranbaxy claims big success with mid-stage malaria drug

While traditional therapies for treating malaria have been steadily losing steam, India's Ranbaxy says that it has nailed positive mid-stage data for a new drug that promises to open a whole new front against the disease. Altogether, researchers tested arterolane on 230 people infected with the most lethal strain of malaria in India, Thailand and Tanzania. The therapy quelled the disease in 72 percent of them after 28 days, offering a similar efficacy profile that had been enjoyed by drugs...